Current investigations into retatruptide peptide highlight significant outlook for addressing weight and type 2 diabetes. The molecule, a dual agonist of GLP-1 and GIP receptor, appears to provide enhanced weight reduction and glucose control versus existing treatments. Further patient studies are necessary to completely determine its safety record